Physician profile
Daniel M Kaplon
NPI 1265651061
$7,780.25
in general payments reported to CMS, 2019-2025
25 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $103 · 2021: $116 · 2022: $2,494 · 2023: $4,164 · 2024: $137 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $739 · Travel and Lodging: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $738.55 |
| Travel and Lodging | $731.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,993.38 | 2022-2023 | Da Vinci Sp, Da Vinci Surgical System |
| Boston Scientific Corporation | $301.87 | 2019-2025 | Lithovue, Spaceoar System, Ams 700 |
| Abbvie INC. | $289.82 | 2022-2025 | |
| Astellas Pharma US INC | $195.50 | 2019 | |
| Procept Biorobotics Corporation | $144.83 | 2022-2024 | Aquabeam System |
| Ethicon US, LLC | $116.86 | 2019-2025 | Harmonic |
| Janssen Biotech, INC. | $109.48 | 2019-2022 | |
| Allergan, INC. | $86.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $77.48 | 2022-2023 | |
| Urogen Pharma, INC. | $70.70 | 2022-2024 | Jelmyto |
| Laborie Medical Technologies Corp. | $57.11 | 2022-2025 | |
| Pfizer INC. | $53.09 | 2019-2020 | |
| 180 Medical, INC. | $36.85 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $33.97 | 2019-2021 | |
| Axonics, INC. | $28.46 | 2022-2024 | Axonics, Bulkamid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $25.37 | 2022 | |
| Smith+Nephew, INC. | $22.37 | 2019 | |
| Telix Pharmaceuticals | $20.27 | 2023 | Illuccix |
| Antares Pharma, INC. | $17.69 | 2023 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $17.64 | 2025 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $17.62 | 2020 | |
| Acerus Pharmaceuticals Corporation | $17.14 | 2021 | |
| Dendreon Pharmaceuticals LLC | $16.60 | 2021 | |
| Baxter Healthcare | $15.41 | 2019 | |
| Amgen INC. | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kaplon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.